(2R)-2-[2-[(1R)-1-(4-Chlorophenylethoxy)]Ethyl]-1-Methyl-2-Pyrrolidine Fumarate

Processing the chiral 2R,1R pyrrolidine fumarate into immediate-release tablet cores forces a narrow set of compaction parameters owing to the high aspect ratio of the 4-chlorophenylethoxy side chain, which orients lamellar slip planes during compression and elevates ejection stress when residual moisture deviates from an equilibrium window of 2.8–3.4 % w/w. Granulation with purified water in a high-shear mixer—typically a Diosna P1/6 or equivalent equipped with a chopper speed maintained at 1,500 rpm—followed by fluid-bed drying to a loss-on-drying endpoint of ≤1.8 % produces a densified intermediate that can be lubricated with 0.75 % w/w sodium stearyl fumarate rather than magnesium stearate, a substitution required to avoid a detectable drop in diastereomeric excess on stability that has been traced to magnesate coordination at the pyrrolidine tertiary amine. Compaction on a rotary press fitted with EU-B tooling and a compression force hold-time above 180 ms yields cores with tensile strength above 2.0 MPa without capping. Regulatory release testing follows USP <905> for uniformity of dosage units, EP 2.9.40 for uniformity of content, and ICH Q3D for elemental impurities; dissolution is profiled in 0.01 N hydrochloric acid using Apparatus 2 at 50 rpm, with a Q value of 80 % at 30 min. Target unit strengths of 1.34 mg, 2.68 mg, and 5.36 mg of the fumarate salt are filled into PVC/PVDC-aluminium blisters under low-oxygen conditions to limit oxidative N-demethylation. The terminal article is a non-sedating antihistamine tablet indicated for symptomatic relief of perennial and seasonal allergic rhinitis and chronic idiopathic urticaria.

Liquid oral dosage forms engineered for paediatric administration exploit the pH-dependent solubility inflection of the fumarate species, which remains poorly ionised above pH 6.0 and consequently adopts a penetrating bitter profile that cannot be masked by mono-sweetener systems alone. A co-processing sequence combining the salt with a cation-exchange resin such as AmberLite™ IRP69 at a drug-to-resin weight ratio of 1:6 in an aqueous slurry, followed by rotor granulation and incorporation into a vehicle thickened with 0.4 % w/v xanthan gum, provides organoleptic coverage sufficient to meet a bitterness score < 1.5 on the five-point Flavor Profile scale when benchmarked against trained panels compliant with ASTM E1909-13. The formulation is preserved with a blend of methylparaben sodium 0.18 % and propylparaben sodium 0.02 % per USP <795> and filled into amber PET containers with a metered oral syringe adapter delivering 0.5 mg of the active per 1 mL; the target concentration is held constant across batches by in-line near-infrared monitoring at 1,460 nm. Downstream filling is conducted in a ISO Class 8 suite with terminal pasteurisation at 85 °C for 120 s validated to achieve a 6-log reduction of Paenibacillus glucanolyticus spores. Finished product is released against ICH Q6A decision trees and the EMA Guideline on pharmaceutical development of medicines for paediatric use, yielding a ready-to-use syrup that avoids ethanol and propylene glycol entirely.

What limits the long-term aqueous stability of the fumarate salt in multi-dose ophthalmic formulations?

Hydrolytic ring-opening of the pyrrolidine ring, catalysed by phosphate anions at the pH 5.8–6.3 range typical of lacrimal-compatible preparations, imposes an upper shelf life of 18 months at 2–8 °C unless the buffer species are excluded in favor of a simple hydrochloric acid-arginine counterpoise at pH 5.5. The ophthalmic solution is compounded at a concentration of 1.0 mg/mL (equivalent to 0.1 % w/v fumarate salt) in Water for Injection, with 0.01 % benzalkonium chloride confirmed by ISO 14729:2017 stand-alone primary acceptance criteria for Pseudomonas aeruginosa and Staphylococcus aureus; tonicity is adjusted with mannitol to 290 mOsmol/kg. Sterilising-grade filtration is performed through a dual 0.22 µm PVDF membrane train immediately upstream of aseptic filling into LDPE primary containers employing steam-sterilised blow-fill-seal technology. Terminal sterilisation is avoided because the ethylene oxide permeation rate through the LDPE wall exceeds the allowable residue limit specified in ISO 10993-7:2008. Visual particulate inspection per USP <771> and sub-visible particulate counts according to Ph.Eur. 2.9.19 must demonstrate < 25 particles ≥ 10 µm per mL, a threshold that occasionally fails in early production batches due to air pocket cavitation around the closure, resolved by installing vacuum-assisted capping with a nitrogen headspace at 0.8 bar gauge pressure. The terminal product is a preservative-containing multi-dose eye drop configured for b.i.d. instillation, targeting acute seasonal conjunctivitis symptoms.

Extrusion melt viscosity and amorphous solid dispersion control for orodispersible films carrying a low-dose antihistamine payload

When a 2.5 mg dose of the pyrrolidine fumarate must be incorporated into a soluble polyvinyl alcohol-polyethylene glycol graft copolymer (Kollicoat® IR) matrix via hot-melt extrusion, the low glass-transition temperature of the drug salt—measured by modulated DSC at 47 °C (midpoint, 10 °C/min heating rate)—limits the processing window to a flat-temperature barrel profile between 115 °C and 130 °C; exceeding 135 °C triggers epimerisation at the stereocenter adjacent to the ether oxygen, detected as a secondary peak at retention time 1.12 relative to the main peak on a Chiralpak® IA-3 column. Extrusion is executed on a co-rotating twin-screw extruder (Leistritz ZSE 18 HPe, L/D 40:1) at a screw speed of 200 rpm and a feed rate of 1.5 kg/h, with the fumarate salt pre-blended at 8 % w/w into the carrier together with 2 % w/w glycerol monolaurate as melt plasticiser and 0.02 % w/w butylated hydroxytoluene as radical scavenger. Torque values above 48 Nm signal over-wetting and require immediate reduction of the liquid feed; real-time melt viscosity data from an in-line slit-die rheometer are correlated against NIR spectra at 1,680 cm⁻¹ to close the loop on screw configuration. The extruded film is calendered to a thickness of 100 µm ± 10 µm and cut into 2 cm × 3 cm units, each delivering the label-claim dose within ± 5 % as assayed by USP <905> adapted for single-unit strips. Dissolution testing in 10 mL water at 37 °C using a small-volume paddle method shows > 85 % release within 60 s, demonstrating suitability for patients with dysphagia. The terminal article is an orodispersible film classified as a solid oral dosage form under ICH Q6A and meeting the disintegration time limits in Ph.Eur. 3.0 (< 3 minutes).

When the molecule serves as a chiral building block for non-sedating histamine H₁ inverse agonists

Beyond its direct use as a finished dose form, the enantiomerically pure fumarate salt acts as a scalable synthetic intermediate for a series of pyrrolidine-based H₁ receptor inverse agonists requiring a pre-installed (R)-configuration at the alpha-carbon to the ether linkage. The most frequent downstream transformation is an N-demethylation-alkylation cascade executed under GMP conditions compliant with ICH Q7: the tertiary amine is first deprotected using 1.05 equivalents of 2,2,2-trichloroethyl chloroformate in refluxing dichloromethane, followed by re-alkylation with a substituted alkyl chloride under phase-transfer conditions (tetrabutylammonium hydrogen sulfate 0.1 mol %, 50 % aqueous sodium hydroxide, toluene, 0–5 °C). The intermediate is introduced at a molar ratio of 1.0:1.0 relative to the alkylating agent, with excess of the chiral pyrrolidine recovered by preparative chiral SFC on a Lux® Amylose-1 column, indicating that published data for this specific synthetic configuration is limited but shows consistent recycling yields above 78 %. Quality attributes monitored include enantiomeric purity by USP <722> (specific optical rotation not less than +12.5°, c=1.0, methanol) and residual palladium when hydrogenolysis steps are invoked for benzyl ether cleavage, kept below 10 ppm as per EMA/CHMP/SWP/4446/2000. The downstream fumarate formation at the second-stage intermediate is effected in acetone-water (3:1 v/v) with cooling to -5 °C over 4 hours, crystallising a white solid with a melting onset of 152–154 °C. The termination of this sequence is a second-generation active pharmaceutical ingredient that exhibits inverse agonism at the human H₁ receptor with an IC₅₀ in the sub-nanomolar range, intended for long-acting oral solid forms.

Galenic development of veterinary chewable units for canine atopic dermatitis departs from human monograph expectations in two respects: palatability excipients disrupt powder flow in a manner that compels granulation endpoint control using acoustic emissions, and the regulatory dissolution sinkers must accommodate a tablet geometry with a center score to permit weight-corrected dosing across body-weight deciles. The active pyrrolidine fumarate is incorporated at 2.0 mg per tablet via wet granulation with microcrystalline cellulose (Avicel® PH-101), lactose monohydrate, and a porcine liver powder adsorbate loaded with 3.5 % w/w of a proprietary meat analogue flavour. Aqueous granulation fluid containing 4 % w/w povidone K30 is delivered into a high-shear mixer to a wet mass endpoint detected by an in-line acoustic sensor (Piper® System) that terminates the liquid addition at a frequency shift from 5.2 kHz to 1.9 kHz, the threshold empirically correlated with a bulk density after drying of 0.65–0.72 g/mL. Drying in a 60 °C fluid-bed dryer to residual moisture not exceeding 2.5 % is followed by compression to hardness 7–9 kP; tablets failing friability (< 0.5 % weight loss according to USP <1216>) are routed back to a dry granulation loop. Manufacturing is conducted under a risk-based supply chain quality framework aligned with VICH GL10 for impurities and VICH GL18 for residual solvents; bioequivalence batch release relies on plasma PK sampling in mixed-breed beagles, measuring T_max at 1.2 hours and C_max variability below 25 % CV. The terminal presentation is a meat-flavoured, bisected chewable tablet for once-daily administration to canines above 6 kg, registered under 21 CFR 514 as a new animal drug application companion indication.